

3 June 2026

ASX Announcement

Nasodine Composition Patent Granted in New Zealand

- **Nasodine pharmaceutical composition patent granted in New Zealand**
- **Already granted in Australia and filed in key markets**
- **Extends overall patent coverage for Nasodine Nasal Spray to 2041**

Firebrick Pharma Limited (ASX: FRE) (the **Company** or **Firebrick**) is pleased to announce that its patent covering the unique formulation of Nasodine® Nasal Spray (“Nasodine”) has been granted in New Zealand.

The patent is titled: “Improved Virucidal Formulations” (NZ Patent Number 794684) and expires in June 2041. The patent was previously granted in Australia and South Africa and has been filed and is pending in the USA, Europe, Canada, Brazil, Israel, Mexico, Philippines, Singapore and Hong Kong.

The basis for the invention claimed in the patent is that the proprietary Nasodine formulation displays enhanced virucidal activity compared with PVP-I solutions alone. According to the patent, the Nasodine formulation “showed a markedly increased virucidal activity compared to other PVP-I formulations (concentrations between around 0.5% and 1.0%), at clinically-relevant exposure times of 2 and 5 minutes.”

The patent also claims the use of the formulation for the purpose of treating a viral infection, and more specifically for reducing mucous secretions, reducing the activity, viability or number of viruses, or reducing the time that virus is present, and thereby reducing the risk of viruses causing secondary illnesses. Specific secondary illnesses covered by the patent include sinusitis, bronchitis and otitis media (middle ear infection).

“Once granted in all key markets, this will be an important additional patent to the Nasodine patent family, because it protects the pharmaceutical formulation of Nasodine, regardless of specific intended use,” said Firebrick Executive Chairman, Dr Peter Molloy. “It also extends the Nasodine patent runway to 2041.”

The other Nasodine patents are ‘method-of-use’ patents covering the use of intranasal povidone-iodine (PVP-I) for the common cold, and its use in pandemic viral diseases.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -



About Firebrick Pharma

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji. Nasodine Nasal Spray was also recently approved for marketing in Indonesia, and the Company is pursuing approval in the Philippines and other markets. Nasodine® Throat Spray is the first follow-on product in the Nasodine range and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit firebrickpharma.com

Contacts:

Media contact:

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com